in silico systems

RockGen Therapeutics is a start-up biotechnology pharmaceutical company developing treatments for neurodegenerative diseases. It uses cutting-edge research into central nervous system diseases to develop novel, disease-modifying medicines, with Amyotrophic Lateral Sclerosis (ALS) as its first target, and broader efforts on Alzheimer's, Parkinson's, Huntington's, and other neurodegenerative disorders. Its pre-clinical work focuses on an anti-aggregating class of drugs.

Read more

drug developmentinnovative chemistrypre-clinical researchwet laboratory systems